cas 916420-27-4|| where to buy tert-butyl 2,4-dichloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate

Produktname:tert-butyl 2,4-dichloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate

IUPAC Name:tert-butyl 2,4-dichloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate

: CAS：916420-27-4; Molekulare Formel：C12H15Cl2N3O2; Reinheit：95%+

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM104183-5g	in stock	ȃƿ
CM104183-10g	in stock	ǪǙǪ
CM104183-25g	in stock	ľĲľ
CM104183-100g	in stock	ůƥŹ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:916420-27-4; Molekulare Formel:C12H15Cl2N3O2; Schmelzpunkt:-; SMILES-Code:CC(C)(C)OC(=O)N1CCC2=C(Cl)N=C(Cl)N=C2C1; Dichte:

: Katalognummer:CM104183; Molekulargewicht:304.17; Siedepunkt:; Mdl-Nr.:MFCD09025732; Lagerung:

: Adagrasib; Jan. 10, 2024, EC approves KRAZATI (adagrasib) as a targeted treatment option for patients with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation.
Adagrasib is an orally available, potent, irreversible, small molecule inhibitor of KRAS G12C mutant isoform for the treatment of solid tumours harbouring KRAS G12C oncogenic driver mutation. Adagrasib covalently binds to the mutant cysteine in KRAS G12C and locks the mutant KRAS protein in its inactive state, thereby preventing downstream signalling without affecting wild-type KRAS protein.